• Company
• Development active for microbiome-based therapies in Korea
• by Nho, Byung Chul Nov 10, 2023 05:19am

• Company
• Will Lixiana hit the 100 billion won mark for the NOAC RX?
• by Kim, Jin-Gu Nov 10, 2023 05:19am

• Company
• Will Trodelbi become a second-line standard tx
• by Nov 9, 2023 05:43am

• Policy
• Korean researchers develop 1st new substance for Alzheimer's
• by Lee, Hye-Kyung Nov 9, 2023 05:43am

• Company
• Prescriptions of HCV market leader Mavyret halves in 1 yr
• by Kim, Jin-Gu Nov 9, 2023 05:43am

• Company
• Velexbru can be prescribed at general hospitals
• by Eo, Yun-Ho Nov 9, 2023 05:43am

• Policy
• Drug pricing nego start in earnest for Tagrisso·Leclaza
• by Lee, Tak-Sun Nov 9, 2023 05:43am

• Policy
• MFDS approves P3T for talquetamab in MM patients
• by Lee, Hye-Kyung Nov 8, 2023 05:37am

• Policy
• Daewoong starts developing XR formulation of tofacitinib
• by Lee, Tak-Sun Nov 8, 2023 05:37am

• Policy
• PN injection benefit restriction suddenly halted
• by Nho, Byung Chul Nov 8, 2023 05:37am